Insider Selling: Lifevantage (NASDAQ:LFVN) Director Sells 12,607 Shares of Stock

Lifevantage Corporation (NASDAQ:LFVN) Director Michael Beindorff sold 12,607 shares of Lifevantage stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $6.42, for a total value of $80,936.94. Following the completion of the sale, the director directly owned 43,806 shares of the company’s stock, valued at approximately $281,234.52. This trade represents a 22.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Lifevantage Stock Performance

NASDAQ LFVN traded up $0.12 during trading on Friday, hitting $6.43. 138,778 shares of the company’s stock traded hands, compared to its average volume of 187,954. The stock has a market capitalization of $81.67 million, a price-to-earnings ratio of 8.69 and a beta of 0.22. Lifevantage Corporation has a 12-month low of $5.98 and a 12-month high of $27.38. The business has a 50 day moving average of $8.71 and a 200-day moving average of $11.40.

Lifevantage (NASDAQ:LFVN) last posted its earnings results on Tuesday, November 4th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.01. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. The firm had revenue of $47.56 million during the quarter, compared to the consensus estimate of $54.74 million. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Lifevantage Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Monday, December 1st will be issued a dividend of $0.045 per share. The ex-dividend date of this dividend is Monday, December 1st. This represents a $0.18 dividend on an annualized basis and a yield of 2.8%. Lifevantage’s payout ratio is presently 23.38%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on LFVN shares. Lake Street Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Lifevantage in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lifevantage in a research note on Monday. Finally, Wall Street Zen downgraded Lifevantage from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.50.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Capital Management Corp VA boosted its stake in Lifevantage by 63.0% during the third quarter. Capital Management Corp VA now owns 2,064,176 shares of the company’s stock valued at $20,084,000 after buying an additional 798,066 shares during the period. Driehaus Capital Management LLC purchased a new stake in shares of Lifevantage in the 1st quarter valued at about $6,701,000. Geode Capital Management LLC raised its holdings in shares of Lifevantage by 106.1% in the 2nd quarter. Geode Capital Management LLC now owns 245,332 shares of the company’s stock valued at $3,210,000 after acquiring an additional 126,274 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Lifevantage by 393,513.8% during the 1st quarter. Russell Investments Group Ltd. now owns 114,148 shares of the company’s stock valued at $1,664,000 after acquiring an additional 114,119 shares during the last quarter. Finally, Trexquant Investment LP purchased a new position in Lifevantage in the 1st quarter worth approximately $1,607,000. Institutional investors own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.